Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop

Pharmacogenomics J. 2006 Mar-Apr;6(2):78-81. doi: 10.1038/sj.tpj.6500345.
No abstract available

Publication types

  • Consensus Development Conference

MeSH terms

  • Drug Design*
  • Drug Industry* / standards
  • Drug Industry* / trends
  • Genetic Markers
  • Pharmacogenetics* / standards
  • Pharmacogenetics* / trends
  • Risk Assessment
  • United States
  • United States Food and Drug Administration

Substances

  • Genetic Markers